A couple points from my take: - Cash balance between last quarter to this quarter : $3.4Million > $6.5Million - $300K in product sales this quarter plus $700K last quarter = $1Million product revenue half year - 2 new manufacturing customers on board - Scope of work for existing customers expanded to continue ongoing work and services revenue - Funding available of $6.475M + $2.667M finance = $9.146M
Regarding CR potential, 2.6 quarters of funding left however, I believe the company is very positive on its ability to complete the FFN contract which has a remaining $4.3Million payable subject to those milestones being achieved. The company also will have furthering revenues from product uptake given the expanded regions in AUS/NZ for the remainder of the flu season and the next quarters will see uptake in further product sales in the US over the coming 2 quarters. Also continued services revenue from current jobs and their 2 new customers.
Pros: 2023 product revenue: $300k > 2024 product revenue: $1.2Million. 25 distribution channels for product in the US alone and 4 more still in negotiation Expanded global footprint this quarter into AUS/NZ and Belgium = expectation for further product growth over the next coming quarters. Expected further distribution news as indicated by Paul (maybe hear more tomorrow)
Future: - Continuation of FFN work with eventual completion and funding. Further indication of ongoing annuities likely announced once project completed. - 4 new distribution channels for product in the US - Product growth in new regions and annual sales given alternating flu markets - 2 new manufacturing clients for ongoing work - Existing services work expanded with continued revenues.
All looking positive.
LDX Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
